These risks and uncertainties include among others results and timing of current and planned preclinical studies and clinical trials of VOXZOGO any potential adverse events observed in the continuing monitoring of the patients in the clinical trials the content and timing of decisions by the European Commission and other regulatory authorities and those factors detailed in BioMarins filings with the Securities and Exchange Commission SEC including without limitation the factors contained under the caption Risk Factors in BioMarins Quarterly Report on Form 10Q for the quarter ended June 30 2023 as such factors may be updated by any subsequent reports